Natera (NTRA) Stock Price, News & Analysis

$105.29
+9.74 (+10.19%)
(As of 05/10/2024 ET)
Today's Range
$101.02
$108.32
50-Day Range
$85.28
$105.29
52-Week Range
$36.90
$108.32
Volume
3.50 million shs
Average Volume
1.18 million shs
Market Capitalization
$12.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$95.13

Natera MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
9.6% Downside
$95.13 Price Target
Short Interest
Bearish
5.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of Natera in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$35 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.35) to ($1.11) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.21 out of 5 stars

Medical Sector

807th out of 925 stocks

Medical Laboratories Industry

17th out of 19 stocks

NTRA stock logo

About Natera Stock (NASDAQ:NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

NTRA Stock Price History

NTRA Stock News Headlines

The ONE AI Stock to own now. (It’s not Nvidia.)
Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …
The ONE AI Stock to own now. (It’s not Nvidia.)
Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …
StockNews.com Downgrades Natera (NASDAQ:NTRA) to Sell
Natera (NTRA) to Release Quarterly Earnings on Thursday
Craig-Hallum Keeps Their Buy Rating on Natera (NTRA)
See More Headlines
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
5/12/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:NTRA
Fax
N/A
Employees
3,293
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$95.13
High Stock Price Target
$137.00
Low Stock Price Target
$68.00
Potential Upside/Downside
-9.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
15 Analysts

Profitability

Net Income
$-434,800,000.00
Pretax Margin
-40.14%

Debt

Sales & Book Value

Annual Sales
$1.08 billion
Book Value
$6.37 per share

Miscellaneous

Free Float
111,580,000
Market Cap
$12.71 billion
Optionable
Optionable
Beta
1.38
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

NTRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Natera stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NTRA shares.
View NTRA analyst ratings
or view top-rated stocks.

What is Natera's stock price target for 2024?

15 Wall Street research analysts have issued 1-year target prices for Natera's stock. Their NTRA share price targets range from $68.00 to $137.00. On average, they expect the company's share price to reach $95.13 in the next twelve months. This suggests that the stock has a possible downside of 9.6%.
View analysts price targets for NTRA
or view top-rated stocks among Wall Street analysts.

How have NTRA shares performed in 2024?

Natera's stock was trading at $62.64 at the start of the year. Since then, NTRA stock has increased by 68.1% and is now trading at $105.29.
View the best growth stocks for 2024 here
.

When is Natera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our NTRA earnings forecast
.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) released its earnings results on Thursday, May, 9th. The medical research company reported ($0.56) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.16. The medical research company earned $367.70 million during the quarter, compared to analysts' expectations of $316.31 million. Natera had a negative trailing twelve-month return on equity of 51.09% and a negative net margin of 30.24%. The company's revenue was up 52.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.23) earnings per share.

What guidance has Natera issued on next quarter's earnings?

Natera issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.4 billion-$1.5 billion, compared to the consensus revenue estimate of $1.3 billion.

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?
When did Natera IPO?

Natera (NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Who are Natera's major shareholders?

Natera's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.15%), Principal Financial Group Inc. (1.13%), Allspring Global Investments Holdings LLC (0.71%), Allspring Global Investments Holdings LLC (0.71%), Zevenbergen Capital Investments LLC (0.40%) and Jennison Associates LLC (0.39%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, John Fesko, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Solomon Moshkevich, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends
.

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NTRA) was last updated on 5/12/2024 by MarketBeat.com Staff

From Our Partners